drugset
drugset / Trial / NCT00465075

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

NCT00465075 ↗

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverOpen-labelPrevention

Summary

The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components.

Timeline

Start
2007-03
Primary completion
—
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg Oral
Subject conjugated estrogens Other / unclassified 0.625 mg Oral

Indications

No indication recorded.